论文部分内容阅读
近来研究表明抗神经节苷酯(GM)1和抗-GDla IgG抗体与急性轴索性周围神经病(轴索型GBS)关系密切,而与急性炎症脱髓鞘性多神经病(脱髓鞘型GBS)无关。虽然多灶性运动神经病中抗-GM1 IgM抗体的诊断价值已经肯定,但抗-GM1 IgG在GBS中的诊断价值尚未明确。Komberg等报道高效价的抗-GM1 IgG对轴索型GBS有特异性,但70例慢性炎症脱髓鞘性多神经病(CIDP)、35例多灶性运动神经病、66例感觉运动多神经病及18例感觉性神经节病均无此自身抗体。然而,有些研究人员认为抗-GM1 IgG缺乏诊断的特异性及临床实用性。Carpo等检测抗-GD1a IgG阳性在GBS为2/73,CIDP为1/20。为此,作者对GBS和CIDP患者进行抗-GM抗体检测,以了解IgG自身抗体的特异性和临床实用性。
Recent studies have shown that anti-ganglioside (GM) 1 and anti-GDla IgG antibodies are closely related to acute axonal peripheral neuropathy (axonal GBS), whereas acute inflammatory demyelinating polyneuropathy (demyelinating GBS) Nothing to do Although the diagnostic value of anti-GM1 IgM antibodies in multifocal motor neuropathy has been confirmed, the diagnostic value of anti-GM1 IgG in GBS is not yet clear. Komberg et al reported that high titer anti-GM1 IgG was specific for axonal GBS, but 70 chronic inflammatory demyelinating polyneuropathy (CIDP), 35 multifocal motor neuropathy, 66 sensory motor polyneuropathy and 18 Cases of sensory ganglion disease without this autoantibody. However, some researchers believe that anti-GM1 IgG lacks diagnostic specificity and clinical utility. Carpo et al. Tested positive for anti-GD1a IgG at 2/20 for GBS and 1/20 for CIDP. To this end, the authors tested anti-GM antibodies in GBS and CIDP patients to understand the specificity and clinical utility of IgG autoantibodies.